Lv21
160 积分 2024-12-03 加入
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
4小时前
已完结
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
3天前
已完结
Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors
5天前
已关闭
Genome-wide transcriptomic response of whole blood to radiation
14天前
已完结
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
29天前
已完结
PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01
1个月前
已完结
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers
2个月前
已完结
PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
2个月前
已完结
Unusual Aspects of Small Cell Carcinoma of the Ovary of Hypercalcaemic Type
2个月前
已完结
SMARCA4/SMARCA2-deficient Carcinoma of the Esophagus and Gastroesophageal Junction
2个月前
已完结
皖公网安备34019202002308
